Faruqi and Faruqui, LLP Logo
Share this page

ProNAi Therapeutics, Inc. (DNAI)



Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In ProNAi Therapeutics, Inc. To Contact The Firm Before Lead Plaintiff Deadline

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in  ProNAi Therapeutics, Inc. (“ProNAi” or the “Company”) (NASDAQ:DNAI) of the January 9, 2017 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against the Company and certain officers.

The lawsuit has been filed in the U.S. District Court for the Southern District of New York on behalf of all those who purchased ProNAi stock or options between July 15, 2015 and June 6, 2016 (the “Class Period”).  The case, Gregory v. ProNAi Therapeutics Inc. et al, No. 16-cv-08703 was filed on November 9, 2016.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by misrepresenting the efficacy and safety of its only product candidate—PNT2258, a drug designed to target cancers that overexpress B-cell lymphoma—and its ability to meet primary and secondary endpoints during clinical trials.

After months of continuously touting PNT2258, on June 6, 2016, the Company issued a press release announcing interim data for the two Phase 2 trials revealing that PNT2258 had failed to produce sufficient efficacy results to justify its continued clinical development. Given the results of these trials, the Company further announced that it would be suspending all clinical development of PNT2258.

After the announcement, ProNAi’s share price fell from $6.38 per share on June 3, 2016 to a closing price of $2.07 on June 6, 2016—a $4.31 or a 67.6% drop.

Take Action

If you invested in ProNAi stock or options between July 15, 2015 and June 6, 2016 and would like to discuss your legal rights, please fill out the form below. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.  Faruqi & Faruqi, LLP also encourages anyone with information regarding ProNAi’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Request Information

Please tell us about yourself by completing the form and we will provide you with additional
information on how to join the Class Action at no cost to you.

  • Case:
    ProNAi Therapeutics, Inc. (DNAI)

* The submission of this form does not create an attorney-client relationship.

Contact Counsel

Richard W. Gonnello
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330


Case Details


  • 11/10/2016

Send Information

If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.